{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:00Z","timestamp":1793386440232,"version":"4.5.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>This study investigated the clinical long-term effect of incobotulinumtoxinA (incoBoNT\/A) in 33 cervical dystonia (CD) patients who had developed partial secondary therapy failure (PSTF) under previous long-term botulinum toxin (BoNT) treatment. Patients were treated four times every 12 weeks with incoBoNT\/A injections. Physicians assessed treatment efficacy using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) at the baseline visit, week 12 and 48. Patients rated quality of life of CD with the Craniocervical Dystonia Questionnaire (CDQ-24). Titres of neutralizing antibodies(NAB) were determined at start of the study and after 48 weeks. All patients had experienced significant and progressive worsening of symptoms in the last 6 months of previous BoNT treatment. Repeated incoBoNT\/A injections resulted in a significant reduction in mean TWSTRS at week 12 and 48. Patients' rating of quality of life was highly correlated with TWSTRS but did not change significantly over 48 weeks. During the 48 weeks -period of incoBoNT\/A treatment NAB titres decreased in 32.2%, did not change in 45.2%, and only increased in 22.6% of the patients. Thus, repeated treatment with the low dose of 200 MU incoBoNT\/A over 48 weeks provided a beneficial clinical long-term effect in PSTF and did not booster titres of NAB.<\/jats:p>","DOI":"10.3389\/fneur.2021.636590","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T10:19:27Z","timestamp":1612865967000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN\u00ae) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins"],"prefix":"10.3389","volume":"12","author":[{"given":"Harald","family":"Hefter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Kahlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Samadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1468-1331.2006.01537.x","article-title":"A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS\/MDS-ES Task Force","volume":"13","author":"Albanese","year":"2006","journal-title":"Eur J Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1468-1331.2006.01439.x","article-title":"Immunological aspects of Botox, Dysport and Myobloc\/NeuroBloc","volume":"13","author":"Dressler","year":"2006","journal-title":"Eur J Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","article-title":"Content of botulinum neurotoxin in Botox\u00ae\/Vistabel\u00ae, Dysport\u00ae\/Azzalure\u00ae, and Xeomin\u00ae\/Bocouture\u00ae","volume":"10","author":"Frevert","year":"2010","journal-title":"Drugs R D"},{"key":"B5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/B978-1-4160-4928-9.00032-9","article-title":"Properties of pharmaceutical products of botulinum neurotoxins","author":"Bigalke","year":"2009","journal-title":"Botulinum Toxin - Therapeutic Clinical Practice & Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1468-1331.2001.00035.x","article-title":"Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions","volume":"8","author":"Aoki","year":"2001","journal-title":"Eur J Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1099\/mic.0.28421-0","article-title":"Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin","volume":"151","author":"Lee","year":"2005","journal-title":"Microbiology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.toxicon.2009.01.017","article-title":"Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins","volume":"53","author":"Kukreja","year":"2009","journal-title":"Toxicon"},{"key":"B9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/mds.870090216","article-title":"Development of resistance to botulinum toxin type A in patients with torticollis","volume":"9","author":"Greene","year":"1994","journal-title":"Mov Disord"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov Disord"},{"key":"B13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s004150050345","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group","volume":"246","author":"Kessler","year":"1999","journal-title":"J Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mdc3.12322","article-title":"High botulinum toxin-neutralizing antibody prevalence under long-term cervical dystonia treatment","volume":"3","author":"Hefter","year":"2016","journal-title":"Mov Disord Clin Pract"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","article-title":"High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy","volume":"92","author":"Albrecht","year":"2019","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s00415-005-0774-3","article-title":"Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure","volume":"252","author":"Dressler","year":"2005","journal-title":"J Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1212\/01.wnl.0000249308.66959.43","article-title":"Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia","volume":"67","author":"Jankovic","year":"2006","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","article-title":"Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products","volume":"15","author":"Frevert","year":"2015","journal-title":"Drugs R D"},{"key":"B19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/exnr.1997.6580","article-title":"Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies\u2013therapeutic consequences","volume":"147","author":"G\u00f6schel","year":"1997","journal-title":"Exp Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/mds.1238","article-title":"Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy","volume":"17","author":"Dressler","year":"2002","journal-title":"Mov Disord"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1002\/mds.20022","article-title":"Clinical presentation and management of antibody-induced failure of botulinum toxin therapy","volume":"19","author":"Dressler","year":"2004","journal-title":"Mov Disord"},{"key":"B22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00702-014-1253-8","article-title":"Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects","volume":"122","author":"Dressler","year":"2015","journal-title":"J Neural Transm"},{"key":"B23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/jnnp.64.5.577","article-title":"Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A","volume":"64","author":"Houser","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.1468-1331.2005.01095.x","article-title":"The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A \u2013 initial experiences","volume":"12","author":"Barnes","year":"2005","journal-title":"Eur J Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/jnnp.65.6.924","article-title":"Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin","volume":"65","author":"Naumann","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/01.wnl.0000252932.71306.89","article-title":"Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia","volume":"68","author":"Hung","year":"2007","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J Neural Transm"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s00415-019-09681-7","article-title":"Effective long-term treatment with incobotulinumtoxin (Xeomin\u00ae) without neutralizing antibody induction: a monocentric, cross-sectional study","volume":"267","author":"Hefter","year":"2020","journal-title":"J Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e000646","DOI":"10.1136\/bmjopen-2011-000646","article-title":"Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinum toxin type A preparation free of complexing proteins \u2013 a single cohort 4-year follow-up study","volume":"2","author":"Hefter","year":"2012","journal-title":"BMJ Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","article-title":"Double-blind study of botulinum toxin in spasmodic torticollis","volume":"2","author":"Tsui","year":"1986","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00702-013-1127-5","article-title":"Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis","volume":"121","author":"Hefter","year":"2014","journal-title":"J Neural Transm"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e000196","DOI":"10.1136\/bmjopen-2011-000196","article-title":"A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis","volume":"1","author":"Hefter","year":"2011","journal-title":"BMJ Open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.baga.2012.03.003","article-title":"CT-guided intramuscular botulinum toxin A injections into the deep anterior neck muscles in patients with pure antecaput or antecollis","volume":"2","author":"Hefter","year":"2012","journal-title":"Basal Ganglia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.baga.2012.04.027","article-title":"Impact of posterior deep neck muscles treatment on cervical dystonia: necessity to differentiate between abnormal positions of head and neck","volume":"2","author":"Hefter","year":"2012","journal-title":"Basal Ganglia"},{"key":"B36","first-page":"1199","article-title":"The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability","volume":"40","author":"Consky","year":"1990","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/jnnp.2003.013441","article-title":"Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument","volume":"75","author":"M\u00fcller","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fneur.2017.00035","article-title":"Clinical practice: evidence-based recommendations for the treatment of cervical dystonia with botulinum toxin","volume":"8","author":"Contarino","year":"2017","journal-title":"Front Neurol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10072-013-1357-1","article-title":"Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence","volume":"34","author":"Ravenni","year":"2013","journal-title":"Neurol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/toxins8030065","article-title":"Conversion ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in clinical practice","volume":"8","author":"Scaglione","year":"2016","journal-title":"Toxins"},{"key":"B41","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov Disord"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s004150170028","article-title":"Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study","volume":"248","author":"Wissel","year":"2001","journal-title":"J Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e001853","DOI":"10.1136\/bmjopen-2012-001853","article-title":"An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport)","volume":"3","author":"Hefter","year":"2013","journal-title":"BMJ Open"},{"key":"B44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?","volume":"32","author":"Lange","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1756286419892078","DOI":"10.1177\/1756286419892078","article-title":"Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia","volume":"12","author":"Hefter","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"B46","first-page":"238","article-title":"Comparative antigenicity of three preparations on botulinum neurotoxin A in the rabbit","volume":"9","author":"Bl\u00fcmel","year":"2006","journal-title":"Neurotox Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000047963","article-title":"Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?","volume":"47","author":"Dressler","year":"2002","journal-title":"Eur Neurol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1099\/00221287-147-4-811","article-title":"Clostridium botulinum type A haemagglutinin-positive progenitor toxin (HA(+)-PTX) binds to oligosaccharides containing Gal beta1-4GlcNAc through one subcomponent of haemagglutinin (HA1)","volume":"147","author":"Inoue","year":"2001","journal-title":"Microbiology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1089\/vim.2006.19.54","article-title":"Ricin toxin B subunit enhancement of rotavirus NSP4 immunogenicity in mice","volume":"19","author":"Choi","year":"2006","journal-title":"Viral Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1504\/TBJ.2008.018956","article-title":"Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use","volume":"1","author":"Panjwani","year":"2008","journal-title":"Botulinum J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1126\/science.1215584","article-title":"Structural basis of TLR5-flagellin recognition and signaling","volume":"335","author":"Yoon","year":"2012","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.4049\/jimmunol.1002156","article-title":"Flagellin as an adjuvant: cellular mechanisms and potential","volume":"185","author":"Mizel","year":"2010","journal-title":"J Immunol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.636590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T10:19:30Z","timestamp":1612865970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.636590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":52,"alternative-id":["10.3389\/fneur.2021.636590"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.636590","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"article-number":"636590"}}